Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Investing.com -- Viking Therapeutics (NASDAQ: VKTX) stock rose 11% Thursday after Eli Lilly’s (NYSE: LLY) data on its oral ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo ...

Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk stock wavered after its second-quarter earnings report early Wednesday as it vowed to cut costs amid ...